Maintaining Hold: A 34% Operating-Earnings Jump That's Mostly FX and an Easy Catastrophe Comp — Meanwhile Cash Hits a Record $382B and the First Deal in Years Barely Dents It
Key Takeaways
- Operating earnings of $13.49B rose 33.6% year-over-year — but the quality is poor. Roughly $1.4B of the gain is a non-cash FX swing (a $331M after-tax remeasurement gain this year against a ~$1.1B loss last year), and the tripling of insurance underwriting to $2.37B is flattered by an easy comparison against a hurricane-hit Q3 2024. Beneath the headline, two of the best engines actually shrank: insurance investment income fell 13.2% as rates eased, and Berkshire Hathaway Energy fell 8.6%.
- The cash pile set a fresh record at $381.7B — up nearly $38B in a single quarter — even as Berkshire again repurchased zero stock (none in the first nine months) and remained a net seller of equities (~$10.6B year-to-date). The capital-allocation logjam we flagged at initiation is, if anything, larger.
- OxyChem is the first crack in the dam. On October 2, Berkshire agreed to acquire Occidental's chemicals business for $9.7B in cash — its biggest acquisition in three years. It is a genuine, welcome signal that capital can still move. It is also ~2.5% of the cash pile, which tells you how far there is to go.
- The stock keeps lagging. BRK-B entered the print up just 5.4% year-to-date against the S&P 500's +16.3% — an 11-point gap — and barely moved on the result (−0.4%). The succession overhang and a cash-heavy, tech-light portfolio in an AI-led market continue to weigh.
- Rating: Maintaining Hold. The operating "beat" is the kind that looks great in a headline and ordinary in the segment table. With the cash still building, no buyback, the stock under-earning the index, and OxyChem too small to change the deployment math, we see no reason to move off neutral — but we are watching the de-rating, which is starting to make the setup more interesting.
Results vs. Expectations
The headline is a 33.6% jump in operating earnings, which sounds like a blowout. It isn't — it is a quarter where the non-operating items broke the right way and the comparison base was soft. Berkshire's own segment table, as always, is where the real read lives.
| Metric (after-tax) | Q3 2025 | Q3 2024 | Y/Y | Read |
|---|---|---|---|---|
| Operating earnings | $13,485M | $10,090M | +33.6% | Up, but FX/comp-flattered |
| Operating EPS (Class B) | ~$6.25 | ~$4.68 | +33.6% | Low-quality gain |
| GAAP net earnings | $30,796M | $26,251M | +17.3% | Equity marks rallied |
| Investment gains (after-tax) | $17,311M | — | — | Non-operating |
| Cash + T-bills | $381.7B | — | Record | +$38B Q/Q |
| Insurance float | ~$176B | ~$171B | +3% | Growing |
| Book value (equity) | $698.2B | — | +$48.8B YTD | ~1.47x P/B |
Operating earnings by segment (after-tax)
| Segment | Q3 2025 | Q3 2024 | Y/Y | Notable |
|---|---|---|---|---|
| Insurance — underwriting | $2,369M | $750M | +216% | Easy comp — Q3'24 was hurricane-hit |
| Insurance — investment income | $3,181M | $3,664M | −13.2% | Rates easing; T-bills reinvest lower |
| Railroad (BNSF) | $1,449M | $1,383M | +4.8% | Operating ratio ~64.2% |
| Utilities & energy (BHE) | $1,489M | $1,629M | −8.6% | US utilities & gas pipelines soft |
| Manufacturing, service & retailing | $3,616M | $3,342M | +8.2% | Steady, broad-based |
| Other (incl. FX on non-USD debt) | $1,381M | −$678M | +$2,059M | ~$331M FX gain vs ~$1.1B loss |
| Operating earnings | $13,485M | $10,090M | +33.6% | Two of six engines actually fell |
Segment Performance
Insurance — Underwriting & GEICO
Underwriting profit tripled to $2,369M after-tax, but read the comparison carefully: the prior-year Q3 was depressed by hurricane losses, so the "triple" is mostly the absence of catastrophes plus favorable prior-year reserve development this year. Within the segment, GEICO is the more interesting story — and it cut both ways this quarter. Premiums earned rose 5.3% to $11,264M and the loss ratio held at a healthy 71.5%, but pre-tax underwriting profit fell 12.8% to $1,773M as the expense ratio jumped 3.2 points to 12.8% on heavier advertising and policy-acquisition spend. The combined ratio of 84.3% is still excellent.
Assessment: The underwriting headline is comp-driven, not a genuine step-change — strip the cat noise and the franchise is steady. The GEICO trade-off is the thing to watch: management is spending to grow policies-in-force again, which compresses near-term margin but builds the book. We are fine with that trade at an 84% combined ratio, but it means GEICO's earnings won't compound in a straight line while the growth investment runs.
Insurance — Investment Income
Investment income fell 13.2% to $3,181M as front-end rates eased and the enormous T-bill book reinvested at lower yields. This is the first quarter the cash-pile tailwind reversed into a headwind.
Assessment: This is the cost of the cash hoard coming into focus. As long as rates were rising or stable, the idle cash quietly padded earnings; now that the front end is drifting lower, the same pile becomes a drag on this line. It sharpens the capital-allocation question — holding $382B in T-bills is not a free option when the yield on that option is falling. Every basis point of rate cut is a direct hit here.
Railroad — BNSF
BNSF earned $1,449M, up 4.8%, on revenue of $5,986M (+1.7%) and volumes up 0.8%. The operating ratio improved again, to roughly 64.2% from ~65.0%, on core pricing and fuel efficiency.
Assessment: The margin-improvement story we flagged last quarter is continuing — a second consecutive quarter of operating-ratio gains. The growth rate cooled from last quarter's fuel-aided +19.5%, which is the more normalized run-rate. BNSF is doing the unglamorous work of closing its margin gap to Union Pacific; steady, not spectacular, and exactly what you want from a railroad.
Utilities & Energy — BHE
BHE earnings fell 8.6% to $1,489M on softness in the US utilities and gas-pipeline operations. Two regulatory overhangs are worth flagging: the One Big Beautiful Bill Act, enacted July 4, accelerates the phase-out of wind and solar production tax credits, which Berkshire is "evaluating" for its capital-spending plans; and the PacifiCorp wildfire litigation remains open, though there were no large fresh accruals this quarter.
Assessment: BHE has gone from a steady grower to a show-me segment. The earnings decline is operational, but the bigger questions are policy-driven — the PTC phase-out could meaningfully alter the renewable-investment economics that underpinned BHE's growth algorithm, and the wildfire tail is still uncapped. We continue to discount this segment inside the sum-of-the-parts until both the policy and litigation pictures clear.
Manufacturing, Service & Retailing
The industrial and consumer collection earned $3,616M, up 8.2% — the most consistent grower in the enterprise, quarter after quarter.
Assessment: Nothing to see here, which is the highest compliment you can pay this segment. Mid-to-high-single-digit growth across dozens of businesses, no drama, no single point of failure. This is the ballast that lets the rest of the company be lumpy.
Other — The FX Swing, In Reverse
"Other" swung to +$1,381M from −$678M, a $2,059M move that is the single largest contributor to the year-over-year operating-earnings gain. The bulk is a $331M after-tax FX remeasurement gain on non-USD debt this quarter, against a ~$1.1B loss in the prior-year quarter.
Assessment: Same caveat as last quarter, opposite direction. This is non-cash remeasurement that nets toward zero over time; it flattered the quarter and should not be capitalized. That a single non-operating line can swing $2B year-over-year — and account for the majority of a "34% earnings jump" — is exactly why we lead with the segment table and treat the operating-earnings total as a starting point, not a conclusion.
Key Themes
OxyChem — Capital Finally Moves (a Little)
On October 2, after quarter-end, Berkshire agreed to acquire Occidental's chemicals business, OxyChem, for $9.7B in cash — its largest acquisition since the 2022 Alleghany deal. OxyChem is a top-three US producer of PVC, chlor-alkali, and chlorinated organics, a steady industrial-chemicals operation that slots naturally into the manufacturing segment.
Assessment: This matters more as a signal than as a number. After years of net selling, dormant buybacks, and a swelling cash pile, the dam has cracked: management found something large enough and cheap enough to clear the hurdle. That partially answers the "can they still deploy?" question we have been pressing. But $9.7B is ~2.5% of the cash pile — the deal closes the gap by an inch, and the cash kept building even after it was announced. Encouraging, not transformative. We want to see the cadence continue before re-rating the optionality.
The Record Cash Pile Keeps Growing
Cash and Treasury bills reached $381.7B, a fresh record, up nearly $38B in the quarter. The operating engine generates cash faster than management deploys it, and the equity sales keep adding to the pile.
Assessment: The pile growing by $38B in a single quarter — even with OxyChem pending — underscores the scale of the deployment challenge. This is no longer just optionality; at $382B it is a structural feature of the balance sheet that the next CEO will inherit and be measured against. With investment income now falling as rates ease, the carrying cost of the hoard is rising just as its yield falls.
Still No Buyback; Still a Net Seller
Berkshire repurchased no stock for the third consecutive quarter (none in the first nine months) and remained a net seller of equities, ~$10.6B year-to-date — though the selling pace has slowed sharply from the ~$127B of the first nine months of 2024.
Assessment: The slowing pace of equity sales is a small tell — management may be finding the market marginally less rich than a year ago, or simply running low on positions it wants to trim. But the continued absence of buybacks at ~1.47x book is the same message as last quarter: the insiders do not see the stock as cheap. We keep weighting that signal heavily.
Capital Allocation & The Cash Question
One quarter on from initiation, the capital-allocation picture has one new data point (OxyChem) layered onto an otherwise unchanged stalemate:
- Acquisitions: OxyChem ($9.7B) is the first sizable deal in three years — a real positive — but it is a fraction of the cash and does not change the run-rate of pile-building.
- Buybacks: Still dormant. Three straight quarters of zero.
- Equities: Still a net seller, though at a slower clip.
- T-bills: Still the residual home for $382B — and now earning less as rates fall.
Assessment: OxyChem nudges the deployment story forward without resolving it. The cash grew faster than the deal absorbed it, the buyback stayed shut, and investment income — the line that made the idle cash tolerable — turned lower. The crux of our Hold is intact: we will pay full price for the optionality only when capital moves at a scale that matters, and one $9.7B deal against a $382B pile is not yet that scale.
Book Value & Valuation
Shareholders' equity rose to $698.2B, up $48.8B year-to-date. Against a post-print market capitalization of roughly $1.03T (at the $475.68 close), the stock trades at about 1.47x book — essentially flat with last quarter and in the middle of its decade-long range. The equity portfolio is $283.2B against an $83.2B cost basis.
The relative-performance gap is the more striking number. BRK-B is up just 5.4% year-to-date while the S&P 500 is up 16.3% — an 11-point shortfall, after the stock had actually been outperforming by ~22 points in early May before the succession announcement. The entire year's relative underperformance has come since the handover was disclosed.
Assessment: The stock is doing exactly what a fairly-valued defensive compounder does in a momentum-led, AI-fueled bull market — lagging. At ~1.47x book it remains fairly priced, not cheap, but the relative de-rating is starting to build the margin of safety we said we wanted at initiation. We are not there yet, but the gap between Berkshire and the index is now wide enough to put a constructive re-rating on our radar for the first time.
Market Reaction
- Pre-print setup: BRK-B closed at $477.54 on Friday, October 31, up 5.4% year-to-date but trailing the S&P 500's +16.3%. The stock had drifted down 4.3% over the trailing 30 days and sat well below its $539.80 all-time high.
- Reaction session (Monday, November 3): Shares opened up 0.4%, traded in a tight $473.15–$479.99 band, and closed at $475.68, down 0.4% on the day. Volume was 5.9M versus a 4.1M 30-day average (1.4x) — modestly elevated but no conviction either way. The S&P 500 was roughly flat (+0.2%).
A 34% operating-earnings headline that moves the stock essentially nowhere is the market doing what we did: looking through the FX-flattered total to the ordinary quarter underneath. The muted reaction also reflects a market that has already made up its mind about Berkshire for now — a fairly-valued, cash-heavy, leadership-in-transition holding that it is content to leave behind while it chases higher-beta growth elsewhere.
Street Perspective
Debate: Does OxyChem signal a deployment pivot or a one-off?
Bull view: OxyChem is the proof of life the deployment skeptics demanded — evidence that Berkshire can still find and close a multi-billion-dollar deal at a sensible price, and a template for absorbing the cash pile one industrial bolt-on at a time.
Bear view: One $9.7B deal after three years of inaction, against a pile that grew $38B in the same quarter, is not a pivot — it is a rounding error. The math of working down $382B through deals this size would take a decade.
Our take: Lean bull on the signal, bear on the scale. OxyChem genuinely improves our confidence that capital can move; it does not yet change the conclusion that the pile is growing faster than it is being deployed. We need a cadence, not a single data point.
Debate: Is the relative underperformance an opportunity or a warning?
Bull view: An 11-point lag to the index in a year is a gift — a fortress balance sheet and best-in-class businesses on sale relative to a frothy, narrow market. Mean reversion plus defensiveness is a setup, not a problem.
Bear view: The lag is rational — Berkshire owns no hyperscalers, holds a quarter of its value in cash, and is changing CEOs. In a market paying up for AI exposure, a slow-compounding industrial holding company deserves to trail.
Our take: It is becoming an opportunity, but it is not one yet. The de-rating is real and the businesses are sound, but we want either a deeper discount or a capital-allocation catalyst before we call the underperformance a buying point. We are closer than we were at initiation.
Debate: Is the cash pile worth its carrying cost now that rates are falling?
Bull view: Even a falling T-bill yield is a positive real return on optionality, and the value of the dry powder is highest precisely when rate cuts signal a softening cycle that could produce the distressed-asset opportunities Berkshire lives for.
Bear view: Investment income just fell 13% and will keep falling as rates drop — the carrying cost of the hoard is rising in real terms, and there is still no sign management will deploy it before the yield erodes.
Our take: The bear has the better of it near-term — the falling-rate environment turns the cash from a quiet earnings tailwind into a quiet drag. The bull's case rests on a dislocation that hasn't arrived. Advantage bear until it does.
Thesis Scorecard
| Thesis Point | Status | Notes |
|---|---|---|
| Bull: Durable, diversified operating engine compounds through cycles | Neutral | BNSF/MSR up, but investment income −13% and BHE −9% this quarter |
| Bull: Fortress balance sheet is unmatched optionality | Improving | OxyChem shows capital can move; pile still growing, though |
| Bull: Relative de-rating creates a margin of safety | Developing | 11-pt YTD lag to S&P; not yet cheap enough to act on |
| Bear: Capital allocation stalled; cash earns falling T-bill yields | Confirmed | Zero buybacks, net seller, investment income now declining |
| Bear: Succession premium compression continues | Confirmed | All of 2025's relative underperformance post-dates the announcement |
Overall: Thesis little changed — a low-quality operating beat, a first deployment data point that's encouraging but small, and a continued relative de-rating that is slowly improving the entry. Net neutral.
Action: Maintaining Hold from our initiation last quarter. The business is fine, the valuation is fair, and the capital-allocation question is unresolved. We are watching the de-rating closely — a deeper discount or a genuine deployment cadence would move us constructive.